The way the brain of a Parkinson’s disease patient is wired may help doctors predict if he or she will develop impulse control disorders following dopamine replacement therapy, a study finds. The results, “The structural connectivity of discrete networks underlies impulsivity and gambling in Parkinson’s disease,”…
News
Both power and strength training can improve muscle performance in people with Parkinson’s disease, but these improvements may not translate to functional movement, a new study has found. The study, titled “Power vs strength training to improve muscular strength, power, balance and functional movement in individuals diagnosed…
Fesoterodine fumarate, the active compound of a medication for overactive bladder, can help reduce urinary symptoms in Parkinson’s disease patients, a clinical study has found. The findings, “Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson’s disease” were published in the World Journal of…
Treatment with Aricept (donepezil) for six weeks does not seem to improve balance, either while standing or walking, for Parkinson’s patients with a minimal history of falls, according to results from a single-site Phase 2 trial. The study, “Effects of augmenting cholinergic neurotransmission on balance in Parkinson’s…
Potential Therapy for Dopaminergic Neurons, CNM-Au8, Enter Phase 2 Trial in Parkinson’s Patients
CNM-Au8, an investigational therapy by Clene Nanomedicine, improved the survival of dopaminergic neurons, helped prevent loss of mitochondria, and rescued motor function in a rat model of Parkinson’s disease, a study reports. The effects of CNM-Au8 will now be assessed in an open-label (no placebo group) Phase 2…
Diabetics Being Treated with Thiazolidinediones May Be at Lower Risk of Parkinson’s, Study Suggests
People with type 2 diabetes being treated with thiazolidinedione compounds, such as Actos (pioglitazone) and Avandia (rosiglitazone), may be at lower risk of Parkinson’s disease, a pilot study suggests. However, more work is needed to confirm a potential to prevent Parkinson’s in an at-risk patient population. The…
A newly developed compound called CM101 helps to clear toxic proteins in the brains of mice, and could be a viable avenue for the treatment of some neurodegenerative diseases, including Parkinson’s disease, researchers say. This finding was recently presented at the annual meeting of the Society of Neuroscience,…
Cannabinoid compounds — particularly cannabidiol (CBD) — show potential to ease symptoms in people with Parkinson’s disease and levodopa-induced dyskinesia (LID), according to a review study. Data also suggests that their therapeutic effects likely involve the direct modulation of critical messenger molecules in the brain and indirect reduction of…
To help Parkinson’s patients identify and discuss their “off episodes” — the return of disease symptoms — with healthcare providers, Acorda Therapeutics is offering a new online tool. Called the “Do Tell” Your Doctor Tool, the questionnaire is used to record such episodes, which can…
Pisa Syndrome Most Likely in Parkinson’s Patients with Axial Symptoms and Sleep Disorder, Study Says
People with Parkinson’s disease are more likely to develop a disabling postural deformity known as Pisa syndrome if they have more severe axial symptoms — such as difficulty with speech or freezing of gait — and a sleep disorder known as rapid eye movement sleep behavior, a study suggests.
Recent Posts
- Loving my uncle meant learning a new way to talk about Parkinson’s
- Genetic factors may hinder treatment in Parkinson’s caused by gene: Case
- Fruit flies help identify genes that may be treatment targets in Parkinson’s
- Getting sick when you already have a chronic illness
- MJFF raises almost $2M in NYC Parkinson’s Unity Walk